CAMPBELL, Calif.–(BUSINESS WIRE)–Saama, a provider of AI-based solutions that accelerate clinical development and commercialization, today announced that it was named a Leader in the “Life Sciences Clinical Data and Analytics (D&A) Platforms PEAK Matrix® Assessment 2023” by Everest Group. This inaugural report evaluates 14 clinical D&A platform providers’ offerings as they relate to market impact as well as vision and capability. Saama is positioned high in the Leaders quadrant for its overall recognition across these categories.
“We are proud to be recognized as a Leader by Everest Group as it underscores the value we deliver to our customers by leveraging the insights within their data to accelerate clinical research,” said Vivek Sharma, Chief Executive Officer, Saama. “By providing a holistic view of both trial operations and patient progress in one location and in real time, the Saama platform empowers researchers with the information they need to drive trial success.”
Saama has nearly a decade of AI research with 90+ models built for life sciences and trained on over 300 million data points. These models are embedded directly within the Saama platform, allowing for the fast and seamless evolution of existing product capabilities to meet the needs of customers today and in the future.
Everest Group’s PEAK Matrix® is a proprietary framework used for evaluating service and technology providers. The dimensions of the matrix include measuring impact created in the market and assessment of vision and capability based on the ability to deliver products successfully.
Saama’s strengths outlined in the report include its:
- Scalable end-to-end clinical data management platform with data analytics and AI capabilities;
- Client perception as a strategic partner that has been tried and tested and brings in high domain and technical expertise;
- Vision that is pragmatic and roadmap-oriented;
- Intuitive platform that is easy to use and navigate; and
- Platform that can integrate all data sources smoothly with accurate search functionalities throughout the databases, leading to easier navigation.
“With Saama as a strategic partner, clinical trial sponsors and CROs have an AI-driven clinical data and analytics platform that enables faster data analysis, optimizes productivity, and provides deeper insights into patient behaviors and progress,” said Lisa Moneymaker, Chief Technology Officer and Chief Product Officer, Saama. “This integration and accessibility to the variety and volume of clinical data available today are critical to getting new treatments to patients.”
The Saama platform of AI-enabled SaaS solutions supports the full spectrum of clinical development. To learn more about the Saama platform and its custom solutions and services or to schedule a personalized demonstration, visit saama.com.
About Saama
Saama develops life science solutions that accelerate the delivery of therapies to patients. With innovative AI technologies, Saama drives breakthrough intelligence into clinical and commercial operations. The Saama platform powered the clinical trial that led to the world’s first COVID-19 vaccine. Headquartered in Campbell, CA, with employees around the globe, Saama is committed to helping customers save and improve lives. Discover more at saama.com.
